Healthcare / Drug Manufacturers - Specialty & GenericKSE
$1299.00
+30.00 (+2.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-233.5M · quality 47.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$237.6B
P/E
N/A
•EV/EBITDA
23.8x
↑ROE
-0.2%
↓Gross Margin
30.3%
↓Debt/Equity
1.03
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
—
FCF margin
-0.1%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $254.26B · net income $-227.7M · FCF $-233.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $254.26B | $254.26B | $252.04B | $234.90B | $218.38B |
| Net Income | $-227.7M | $-227.7M | $1.23B | $-3.88B | $-21.96B |
| EBITDA | $12.76B | $12.76B | $16.87B | $7.65B | $-14.30B |
| EPS | -1.00 | -1.00 | 7.00 | -21.00 | -120.00 |
| Gross Margin | 30.3% | 30.3% | 31.9% | 30.7% | 29.6% |
| Operating Margin | 1.9% | 1.9% | 3.5% | 1.3% | -3.4% |
| Net Margin | -0.1% | -0.1% | 0.5% | -1.6% | -10.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.03 | 1.03 | 0.72 | 0.75 | 0.44 |
| Current Ratio | 2.96 | 2.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-233.5M | $-233.5M | $133.7M | $-20.46B | $-24.81B |
| Returns | |||||
| ROE | -0.2% | -0.2% | 1.4% | -4.3% | -24.4% |
| Valuation | |||||
| P/E | — | — | 293.57 | — | — |
| EV/EBITDA | 23.76 | 23.76 | 25.93 | 59.06 | — |
| P/B | 2.60 | 2.60 | 4.19 | 4.38 | 6.50 |
| Growth & Yield | |||||
| Revenue Growth | 0.9% | 0.9% | 7.3% | 7.6% | — |
| EPS Growth | -114.3% | -114.3% | 133.3% | 82.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.4%
Start / end P/E
n/dx → n/dx
EPS bridge
7.00 → -1.00
Residual
-40.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.